Tim Cortese

Disitamab vedotin plus toripalimab significantly enhances survival rates in HER2-expressing advanced urothelial carcinoma, outperforming standard chemotherapy.

New findings reveal pembrolizumab combined with paclitaxel enhances survival rates in patients with platinum-resistant recurrent ovarian cancer.

Belantamab mafodotin (Blenrep), pomalidomide (Pomalyst), and dexamethasone (BPd) was well tolerated and led to deep responses in patients with high-risk multiple myeloma.

Sevabertinib shows promising efficacy in treating HER2-mutant advanced NSCLC, achieving high response rates and durable outcomes in clinical trials.

Combination therapy of casdatifan and cabozantinib shows promising efficacy and manageable safety in patients with advanced clear cell renal cell carcinoma.

Nivolumab and relatlimab show promising intracranial activity in melanoma brain metastases, highlighting potential for further research in resistant cases.

Daratumumab enhances treatment efficacy in newly diagnosed multiple myeloma, showing improved MRD negativity and progression-free survival in recent clinical trials.

The FIRST/ENGOT-OV44 trial found dostarlimab plus platinum-chemo and niraparib maintenance modestly improved PFS (20.6 vs 19.2 months) in advanced ovarian cancer, with expected safety.

The ALNEO trial's final analysis shows neoadjuvant alectinib is effective and well tolerated in resectable stage III ALK-positive NSCLC, achieving 42% MPR and 67% ORR, suggesting a feasible perioperative option.

EMBER-3 trial results show imlunestrant, alone or with abemaciclib, improves patient-reported outcomes for ER+/HER2- advanced breast cancer after endocrine therapy.

T-DXd significantly improved overall survival vs ramucirumab/paclitaxel in second-line HER2-positive unresectable/metastatic gastric/GEJ cancer.

Oral selinexor as maintenance therapy extended progression-free survival in patients with TP53 wild-type advanced or recurrent endometrial cancer.

Frailty assessments, particularly the G8 tool, BMI, and albumin, may identify mHSPC patients at higher risk for severe adverse events with upfront docetaxel, a study suggests.

Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and increased risk of neurotoxicity in a cohort study.

Cemiplimab plus chemotherapy showed efficacy and consistent safety in advanced penile cancer in the phase 2 EPIC trial.

Nivolumab plus cabozantinib improved long-term efficacy and safety vs sunitinib in advanced renal cell carcinoma, per final CheckMate 9ER trial results.

Palliative care consultations in esophageal cancer improved QOL and reduced financial burden, according to ASCO GI poster findings.

SCRT plus cadonilimab and chemotherapy showed positive pCRs and acceptable safety in pMMR/MSS locally advanced rectal cancer.

SHR-1701, a PD-L1 and TGF-ß targeting agent, reduced chemotherapy-induced myelosuppression in patients with HER2-negative gastric/GEJ adenocarcinoma.

The combination of everolimus plus lanreotide showed an improvement in progression-free survival and an acceptable safety profile vs everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.

In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.

Erythropoietin stimulating agents and/or luspatercept showed positive clinical efficacy and safety in patients with VEXAS syndrome, with or without MDS.

The phase 2 LODEFI study showed that low-dose deferasirox achieved transfusion independence and was well-tolerated in low-risk anemic MDS.